FIELD: medicine; physiology; neurobiology.
SUBSTANCE: invention can be used to determine the biocompatibility of scaffolds for neurotransplantation. A traumatic brain injury is created in the animal, the damaged area is removed, and a scaffold is implanted in the area of the injury. Determination of the neurological status of animals, intravital visualization of the dynamics of morphological changes in brain tissue in the area of implantation, assessment of the general motor and orientational-exploratory activity of the animal using the Open Field test, assessment of short-term and/or long-term memory in the post-traumatic period using the passive avoidance conditioned reflex test and the Morris water maze test, assessment of morphometric parameters of histological examination of brain tissue in the implantation zone. The biocompatibility of the scaffold is determined by examining the neurological deficit of the animal at least 2 months after implantation. A positive result of biocompatibility is achieved with the simultaneous fulfilment of several conditions: preservation of the general motor and orientation-exploratory activity of animals in the post-traumatic period; preservation of animals' abilities to learn and remember information; reduction in the focus of inflammation in the brain of animals relative to the control by 1.2 times.
EFFECT: method provides an assessment of the risks of developing pathological reactions that can lead to rejection of the transplanted material by nervous tissue, due to the stated conditions.
3 cl, 6 dwg, 3 tbl
Title | Year | Author | Number |
---|---|---|---|
CARRIER FOR TRANSPLANTABLE CELLS FOR REPLACEMENT OF A DEFECT OBTAINED WITH A HEAD INJURY | 2016 |
|
RU2659842C2 |
METHOD FOR IN VITRO DETERMINATION OF BIOCOMPATIBILITY OF SCAFFOLDS FOR NEUROTRANSPLANTATION | 2020 |
|
RU2776455C2 |
NEURORABILITATION AGENT BASED ON SODIUM 6-OXO-1-PHENYL-2-(PHENYLAMINO)-1,6-DIHYDROPYRIMIDINE-4-OLATE | 2018 |
|
RU2675694C1 |
METHOD FOR CORRECTING NEUROLOGICAL DEFICIENCY OF 2-AMINO-5-ETHYL-1,3,4-THIODIAZOLIUM-N-ACETYL-AMINOETHANOATE IN TRAUMATIC BRAIN INJURY | 2021 |
|
RU2758433C1 |
METHOD FOR CORRECTION OF PATHOLOGY OF 2-AMINO-5-ETHYL-1,3,4-THIODIAZOLIUM-N-ACETYL-AMINOETHANOATE IN TRAUMATIC BRAIN INJURY | 2021 |
|
RU2766785C1 |
METHOD FOR MODELING CRANIOCEREBRAL INJURY WITH PERSISTENT NEUROLOGICAL DEFICIENCY | 2020 |
|
RU2739700C1 |
METHOD FOR CORRECTING BEHAVIORAL STATUS OF 2-AMINO-5-ETHYL-1,3,4-THIODIAZOLIUM-N-ACETYL-AMINOETHANOATE IN TRAUMATIC BRAIN INJURY | 2021 |
|
RU2756325C1 |
METHOD FOR SEVERE CRANIOCEREBRAL INJURY SIMULATION | 2016 |
|
RU2641569C1 |
METHOD FOR CORRECTING THE BEHAVIORAL STATUS OF 2-AMINO-5-ETHYL-1,3,4-THIODIAZOLIUM-N-ACETYL-AMINOETHANOATE IN CASE OF BRAIN DAMAGE | 2021 |
|
RU2763012C1 |
MEDICATION, PROVIDING NEURO-PROTECTIVE ACTION IN ACUTE PERIOD OF CRANIOCEREBRAL INJURY | 2009 |
|
RU2414901C2 |
Authors
Dates
2024-01-30—Published
2021-12-16—Filed